Secondary prophylaxis therapy: what are the benefits, limitations and unknowns?
about
Rationale for a randomized controlled trial comparing two prophylaxis regimens in adults with severe hemophilia A: the Hemophilia Adult Prophylaxis Trial.Treatment of hemophilia: a review of current advances and ongoing issuesRofecoxib as adjunctive therapy for haemophilic arthropathy.Optimizing outcomes for patients with severe haemophilia A.Staunch protections: the ethics of haemophilia gene transfer research.Secondary prophylaxis in adolescent and adult haemophiliacs.The history and evolution of the clinical effectiveness of haemophilia type a treatment: a systematic review.Novel drugs to treat hemophilia.Past, present and future of hemophilia: a narrative review.Management of joint bleeding in hemophilia.Considerations in individualizing prophylaxis in patients with haemophilia A.New and Emerging Agents for the Treatment of Hemophilia: Focus on Extended Half-Life Recombinant Clotting Proteins.Novel, human cell line-derived recombinant factor VIII (human-cl rhFVIII; Nuwiq(®) ) in adults with severe haemophilia A: efficacy and safety.Physician trust and depression influence adherence to factor replacement: a single-centre cross-sectional study.A consensus statement on clinical trials of bypassing agent prophylaxis in inhibitor patients.Predictors of non-adherence to prescribed prophylactic clotting-factor treatment regimens among adolescent and young adults with a bleeding disorder.Prophylaxis for adults with haemophilia: one size does not fit all.Is on-demand treatment effective in patients with severe haemophilia?Considerations in the evaluation of haemophilia patients for short-term prophylactic therapy: a paediatric and adult case study.Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects.Better adherence to prescribed treatment regimen is related to less chronic pain among adolescents and young adults with moderate or severe haemophilia.Adherence to clotting factors among persons with hemophilia A or B.Pathogenesis of haemophilic synovitis: clinical aspects.Arthroscopic synovectomy in haemophilia: indications, technique and results.Prophylaxis and treatment of chronic synovitis in haemophilia patients with inhibitors.The impact of joint bleeding and synovitis on physical ability and joint function in a murine model of haemophilic synovitis.The co effect of prophylaxis and radiosynovectomy on bleeding episodes in haemophilic synovitis.Changing pattern of care of boys with haemophilia in western European centres.Synovitis in a murine model of human factor VIII deficiency.Short-term low-dose secondary prophylaxis for severe/moderate haemophilia A children is beneficial to reduce bleed and improve daily activity, but there are obstacle in its execution: a multi-centre pilot study in China.Prolonged effect of a new O-glycoPEGylated FVIII (N8-GP) in a murine saphenous vein bleeding model.
P2860
Q35311771-AC5A829A-E149-4145-91F3-F4C388342579Q35683781-F2EBD2A8-1AC2-4522-8A39-55B53CCB781BQ36117538-31BF642F-3B81-42B6-87AB-CF78DE4E2BB3Q36932769-3855714B-2651-49F0-85AC-993452333441Q37001594-CE542FF7-41D3-4E26-B4A0-8B6E262A39C8Q37119647-D7BAD61F-E08E-4FFB-A11E-11DD4FB49909Q37578173-C4E34D6F-93DD-4065-9E9C-BBBAC5D14514Q37775029-A70D715E-22AE-4780-AA93-2C785990C2D8Q38007018-D62F770F-532A-4B42-929B-C446777D4D4BQ38044778-F2416EA8-0882-49C1-B879-F33C2B6BCAD0Q38203021-8BD542B8-BF92-4F03-8381-7ECD80D62C51Q38574414-BCB8D1D5-2CA0-4EF1-9914-5A70D90AAE8EQ38840145-96943172-11B4-4363-B0FA-42B8379CB008Q39338258-8C1B66C9-BFBF-45A8-A6A0-E964097B3691Q39776012-96B0023B-C01C-42BA-91D8-4C1BFD0B1B21Q40739601-795E5EFA-86FA-44C7-BC1E-F17F312C8E4EQ42555149-994C130C-CADE-4173-BF00-A3BA759DAF17Q44456496-9D8A65FC-1A56-4E5A-A9BD-406C03E5B955Q45855111-0C5D57AD-8FAF-4358-A74B-DF4B2EE8E0D3Q45861492-2BC86C85-E832-453D-AE84-629C48F88528Q45862373-B469C9C9-17A3-4345-8C75-3FDD2979BD45Q45866634-94EC9725-8262-4874-8492-F58F6DE9AD64Q45870769-A19C43FC-215E-4B38-BE5B-CA296C568F6DQ45870796-FA5C1EB4-7204-4F63-8068-DBF13BC62371Q45870800-5C871364-079E-4FBA-87CB-86B89F400193Q45874320-B1A56F9C-E7DB-4585-99A9-E34A80573F82Q45874958-42AF1DDA-D8EA-45DE-8C55-118E3431527DQ45882439-93FE03DF-7B85-4025-B7FA-1C37266A96F9Q45883299-E05C9B13-2A16-4BB8-9BE8-36EDEF1E36D3Q45883686-611B87F5-DB7C-434A-B619-740A955A7765Q45887979-CA8533C8-0632-455D-90FF-B5D47DFC62F6
P2860
Secondary prophylaxis therapy: what are the benefits, limitations and unknowns?
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Secondary prophylaxis therapy: what are the benefits, limitations and unknowns?
@ast
Secondary prophylaxis therapy: what are the benefits, limitations and unknowns?
@en
type
label
Secondary prophylaxis therapy: what are the benefits, limitations and unknowns?
@ast
Secondary prophylaxis therapy: what are the benefits, limitations and unknowns?
@en
prefLabel
Secondary prophylaxis therapy: what are the benefits, limitations and unknowns?
@ast
Secondary prophylaxis therapy: what are the benefits, limitations and unknowns?
@en
P2860
P1433
P1476
Secondary prophylaxis therapy: what are the benefits, limitations and unknowns?
@en
P2093
Valentino LA
P2860
P304
P356
10.1111/J.1365-2516.2003.00870.X
P577
2004-03-01T00:00:00Z